Accumulated Other Comprehensive Income (Loss), Net of Tax in USD of Unity Biotechnology, Inc. from Q4 2017 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
Unity Biotechnology, Inc. quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax history and change rate from Q4 2017 to Q1 2025.
  • Unity Biotechnology, Inc. Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending 31 Mar 2025 was $1K.
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Change (%)

Unity Biotechnology, Inc. Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax (USD)

Period Value YoY Chg Change % Date Report Filed
Q1 2025 $1K +$39K 31 Mar 2025 10-Q 22 Apr 2025
Q4 2024 $15K +$39K 31 Dec 2024 10-Q 22 Apr 2025
Q3 2024 $39K +$94K 30 Sep 2024 10-Q 04 Nov 2024
Q2 2024 -$35K +$101K +74.3% 30 Jun 2024 10-Q 06 Aug 2024
Q1 2024 -$38K +$112K +74.7% 31 Mar 2024 10-Q 14 May 2024
Q4 2023 -$24K +$227K +90.4% 31 Dec 2023 10-K 07 Mar 2025
Q3 2023 -$55K +$220K +80% 30 Sep 2023 10-K 15 Apr 2024
Q2 2023 -$136K +$51K +27.3% 30 Jun 2023 10-K 15 Apr 2024
Q1 2023 -$150K +$26K +14.8% 31 Mar 2023 10-K 15 Apr 2024
Q4 2022 -$251K -$207K -470% 31 Dec 2022 10-K 15 Apr 2024
Q3 2022 -$275K -$281K -4683% 30 Sep 2022 10-K 15 Apr 2024
Q2 2022 -$187K -$192K -3840% 30 Jun 2022 10-Q 12 Aug 2022
Q1 2022 -$176K -$191K -1273% 31 Mar 2022 10-Q 10 May 2022
Q4 2021 -$44K -$49K -980% 31 Dec 2021 10-K 15 Mar 2023
Q3 2021 $6K -$60K -90.9% 30 Sep 2021 10-Q 10 Nov 2021
Q2 2021 $5K -$227K -97.8% 30 Jun 2021 10-Q 10 Aug 2021
Q1 2021 $15K -$358K -96% 31 Mar 2021 10-Q 11 May 2021
Q4 2020 $5K -$85K -94.4% 31 Dec 2020 10-K 15 Mar 2022
Q3 2020 $66K -$29K -30.5% 30 Sep 2020 10-Q 04 Nov 2020
Q2 2020 $232K +$119K +105% 30 Jun 2020 10-Q 31 Jul 2020
Q1 2020 $373K +$354K +1863% 31 Mar 2020 10-Q 07 May 2020
Q4 2019 $90K +$185K 31 Dec 2019 10-K 23 Mar 2021
Q3 2019 $95K +$214K 30 Sep 2019 10-Q 06 Nov 2019
Q2 2019 $113K +$190K 30 Jun 2019 10-Q 07 Aug 2019
Q1 2019 $19K +$157K 31 Mar 2019 10-Q 08 May 2019
Q4 2018 -$95K +$9K +8.65% 31 Dec 2018 10-K 11 Mar 2020
Q3 2018 -$119K 30 Sep 2018 10-Q 07 Nov 2018
Q2 2018 -$77K 30 Jun 2018 10-Q 09 Aug 2018
Q1 2018 -$138K 31 Mar 2018 10-Q 07 Jun 2018
Q4 2017 -$104K 31 Dec 2017 10-K 06 Mar 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.